BioSpace News Archive

MoonLake Immunotherapeutics, a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, announced the pricing on June 27, 2023 of its upsized underwritten public offering of 8,000,000 Class A ordinary shares at a public offering price per share of $50.00.

Karyopharm Therapeutics Inc. today announced the initiation of a pivotal Phase 3 clinical trial (XPORT-MF-034) (NCT04562389) to assess the efficacy and safety of once-weekly selinexor 60mg in combination with ruxolitinib in JAKi-naïve patients with myelofibrosis.

K36 Therapeutics (“K36"), a privately held clinical-stage biotech company developing KTX-1001.

Truvian Health the company will present findings from initial clinical validation studies of its blood testing solution at the 2023 American Association of Clinical Chemistry (AACC) Annual Scientific Meeting in Anaheim, Calif.

The New Hope Research Foundation and Forge Biologics announced today a development and cGMP manufacturing partnership to advance the Foundation’s novel gene therapy, NHR01, into Phase I/II clinical trials for patients with GM2 gangliosidosis,

Spago Nanomedical AB announces that a preliminary analysis of data from the phase IIa clinical study SPAGOPIX-02 shows that SN132D has a good safety profile in patients with endometriosis.

Verona Pharma plc, announces the American Journal of Respiratory and Critical Care Medicine has published results from its Phase 3 ENHANCE trials evaluating ensifentrine in chronic obstructive pulmonary disease.

AstraZeneca has announced a $400 million investment in its global AZ Forest programme, raising its commitment to plant 200 million trees by 2030 and ensure their long-term survival.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”) today announced that the Company has been awarded a $2.0 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support the clinical development of REM-001, a second-generation photodynamic therapy photosensitizer agent for the treatment of cutaneous metastatic breast cancer (CMBC).

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.